Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 13;18(1):204.
doi: 10.1186/s12957-020-01987-5.

Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China

Xiao-Hai Song  1 , Wei-Han Zhang  1 , Kai-Liu  1 , Xiao-Long Chen  1 , Lin-Yong Zhao  1 , Xin-Zu Chen  1 , Kun-Yang  1 , Zong-Guang Zhou  2 , Jian-Kun Hu  3
Affiliations

Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China

Xiao-Hai Song et al. World J Surg Oncol. .

Abstract

Background: Due to the controversy over the prognostic significance of Borrmann type in patients with gastric cancer (GC), the present study was to investigate the clinical value of Borrmann type in advanced GC.

Methods: We retrospectively evaluated 2092 patients with advanced GC and subsequently examined the clinicopathological characteristics and prognosis of patients stratified by Borrmann type.

Results: Patients were divided into three groups according to Borrmann type (Borrmann types I+II, III, and IV). Patients with Borrmann types III and IV had larger size, more poorly differentiated tumor type, more advanced tumor stage, and higher chance of involving the entire stomach. The overall survival (OS) rates were significantly different among the three groups (p < 0.001). Stratification analysis revealed significant OS rates among the three groups in tumor-node-metastasis (TNM) stage III (p < 0.001) and TNM stage IV (p = 0.008). Multivariate analysis revealed that Borrmann types, adjuvant chemotherapy, curative resection, and TNM stage were all independent predictors of OS among GC patients. The subgroup analysis indicated that Borrmann type was an independent predictor of OS among GC patients who undergone curative resection and with TNM stage III cancer. However, curative resection and postoperative chemotherapy failed to prolong the survival of patients with Borrmann type IV.

Conclusions: The clinicopathological characteristics and prognosis of patients with three Borrmann types of GC were different. Borrmann type can be simply used as a valuable factor to predict survival in advanced GC patients, especially in those TNM stage III undergoing curative resection. Additionally, more attention should be paid to the treatment for Borrmann type IV GC.

Keywords: Borrmann type; Clinicopathological features; Gastric cancer; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors indicate no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
The flow chart of included patients in this study
Fig. 2
Fig. 2
Comparation of survival curves between Borrmann type I+II, III, and IV gastric cancer
Fig. 3
Fig. 3
Comparation of survival curves between Borrmann type I+II, III, and IV gastric cancer in TNM stage I (a), II (b), III (c), and IV(d)
Fig. 4
Fig. 4
Comparation of survival curves between Borrmann type I+II, III, and IV gastric cancer in patients with curative resection (a) and in subgroup TNM III (b)
Fig. 5
Fig. 5
Comparation of survival curves between patients with curative resection and with noncurative resection in Borrmann I+II (a), Borrmann III (b), and Borrmann IV (c)
Fig. 6
Fig. 6
Comparation of survival curves between patients with chemotherapy and without chemotherapy in Borrmann I+II (a), Borrmann III (b), and Borrmann IV (c)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. LANCET ONCOL. 2010;11(5):439–449. doi: 10.1016/S1470-2045(10)70070-X. - DOI - PubMed
    1. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730. doi: 10.1056/NEJMoa010187. - DOI - PubMed
    1. Sherman KL, Merkow RP, Bilimoria KY, Wang CE, Mulcahy MF, Benson AB, Bentrem DJ. Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. Ann Surg Oncol. 2013;20(2):362–370. doi: 10.1245/s10434-012-2552-7. - DOI - PubMed
    1. Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, Iwamoto K, Yashima R, Yamauchi H, Kikuchi S. Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol. 2004;39(4):380–384. doi: 10.1080/00365520310008629. - DOI - PubMed